BMS-214662 in Treating Patients With Advanced Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00006242
First received: September 11, 2000
Last updated: January 31, 2013
Last verified: January 2013

September 11, 2000
January 31, 2013
July 2000
September 2005   (final data collection date for primary outcome measure)
  • Maximum tolerated dose (MTD) of BMS-214662, based on the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0 [ Time Frame: Up to 28 days ] [ Designated as safety issue: Yes ]
  • Adverse events, based on the NCI CTC v2.0 [ Time Frame: Up to 5 years ] [ Designated as safety issue: Yes ]
  • Plasma concentration-time profile of BMS-214662 when given as a continuous IV infusion escalating to 24 hr [ Time Frame: Up to 48 hours ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00006242 on ClinicalTrials.gov Archive Site
  • Determination whether the pharmacokinetic behavior is linear as dose is escalated [ Time Frame: Up to 48 hours ] [ Designated as safety issue: No ]
  • Determination of dose that provides potentially effective level of systemic exposure to the drug as indicated by information from preclinical studies [ Time Frame: Up to 48 hours ] [ Designated as safety issue: Yes ]
  • Interpatient variability in the steady state plasma concentration (C^ss) and other pharmacokinetic variables in patients treated at the MTD peak [ Time Frame: Up to 48 hours ] [ Designated as safety issue: No ]
  • Correlations between pharmacokinetic variables and pretreatment laboratory values, toxicity, and indications of biological response (farnesyltransferase activity) [ Time Frame: Up to 48 hours ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
BMS-214662 in Treating Patients With Advanced Solid Tumors
A Phase I Trial of Farnesyltransferase Inhibitor BMS-214662 (NSC 710086) Escalating to a 24 Hour Continuous Intravenous Infusion in Patients With Solid Tumors

Phase I trial to study the effectiveness of BMS-214662 in treating patients who have advanced solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

PRIMARY OBJECTIVES:

I. To establish the maximum tolerated dose (MTD) and identify the dose limiting toxicities (DLT) of the investigational agent BMS-214662 when escalated to a 24-hour continuous intravenous infusion every 7 days for 3 consecutive weeks to patients with solid tumors who have failed curative or survival prolonging therapy or for who no such therapies exist.

II. To establish and assess the safety of an appropriate dose for Phase II studies.

III. To characterize the pharmacokinetics of BMS-214662 in patients when escalated to a 24-hour continuous IV infusion.

IV. To assess the extent and duration of farnesyltransferase inhibition in peripheral blood mononuclear cells and other relevant surrogate markers of pharmacological activity.

SECONDARY OBJECTIVES:

I. To describe any preliminary evidence of antitumor activity. II. To establish pharmacodynamic relationships for the pharmacological effect of the drug upon surrogate markers of activity and host toxicity.

III. To compare the toxicity profiles for the 1 hour IV infusion and 24 hr continuous IV infusion administration schedules, assuming that the 24 hr infusion schedule is feasible.

OUTLINE: This is a dose-prolongation, dose-escalation study.

Single patient cohorts receive BMS-214662 IV over escalating periods of 2, 4, 8, 16, and 24 hours weekly for 3 weeks followed by 1 week of rest. If no patient experiences dose-limiting toxicity (DLT), dose escalation proceeds in the single patient cohorts.

Treatment repeats every 4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Individual patient cohorts may increase their duration of BMS-214662 infusion in subsequent courses to the current duration safely reached.

Beginning with the infusion level at which DLT is first encountered by a single patient, cohorts of 3-6 patients receive escalating doses of BMS-214662 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. An additional cohort of 10 patients is treated at the MTD.

Patients are followed for at least 4 weeks.

PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 9-12 months.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Unspecified Adult Solid Tumor, Protocol Specific
  • Drug: BMS-214662
    Given IV
    Other Names:
    • farnesyltransferase inhibitor BMS-214662
    • FTI BMS 214662
  • Other: laboratory biomarker analysis
    Correlative studies
  • Other: pharmacological study
    Correlative studies
    Other Name: pharmacological studies
Experimental: Treatment (BMS-214662)

Single patient cohorts receive BMS-214662 IV over escalating periods of 2, 4, 8, 16, and 24 hours weekly for 3 weeks followed by 1 week of rest. If no patient experiences DLT, dose escalation proceeds in the single patient cohorts.

Treatment repeats every 4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Individual patient cohorts may increase their duration of BMS-214662 infusion in subsequent courses to the current duration safely reached.

Beginning with the infusion level at which DLT is first encountered by a single patient, cohorts of 3-6 patients receive escalating doses of BMS-214662 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. An additional cohort of 10 patients is treated at the MTD.

Interventions:
  • Drug: BMS-214662
  • Other: laboratory biomarker analysis
  • Other: pharmacological study
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
Not Provided
September 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Metastatic or inoperable malignancy, other than leukemia or a primary CNS tumor, for which there is no known curative or survival prolonging palliative therapy, or failure of these therapies
  • Life expectancy >= 2 months
  • ECOG performance status 0-1
  • ANC >= 1,500/mm^3
  • Platelets >= 100,000/mm^3
  • SGOT and SGPT =< 2.5 times the upper limit of normal (ULN)
  • Total bilirubin =< ULN
  • Serum creatinine =< ULN
  • Calculated or measured creatinine clearances (Cockcroft-Gault formula) >= 50 ml/minute
  • >= 3 weeks since major surgery
  • >= 4 weeks since chemotherapy or radiation therapy
  • No uncontrolled serious medical or psychiatric illness
  • Women of childbearing potential must not be pregnant or lactating; all women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L of beta-HCG) within 72 hr prior to receiving the study medication; BMS 214662 has antiproliferative effects which may be harmful to the developing fetus or nursing infant
  • Fertile males and females must use adequate contraception
  • Signed informed consent

Exclusion Criteria:

  • Any history of clinically significant atrial or ventricular arrhythmias, any history of second or third degree heart block, or prolonged QTc interval (greater than 450 ms) on electrocardiogram
  • Active brain metastases including evidence of cerebral edema by CT scan or MRI, or progression from prior imaging study, any requirement for steroids, or clinical symptoms of/from brain metastases
  • Received any drugs within 7 days prior to receiving study drug therapy, which are known to be substrates of cytochrome P450-3A4 (CYP3A4)
  • Patients should not receive concurrent therapy with known CYP3A4 substrates while on study and for at least 1 week following the last dose of BMS-214662; this is due to the CYP3A4 inhibitory potential of BMS-214662; a representative list of commonly prescribed known CYP3A4 substrates includes: terfenadine, astemizole, triazolam, midazolam, cisapride, bepridil, rifabutin, simvastatin, lovastatin, and propafenone
  • Patients receiving therapy with BMS-214662 should not receive concomitant therapy with NSAIDs or other potentially nephrotoxic medications for at least 2 days before and after administration of BMS-214662
  • Patients with known pre-existing renal disease are not eligible
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00006242
NCI-2013-00032, 00-003, U01CA062490, CDR0000068170
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Joseph Eder Dana-Farber Cancer Institute
National Cancer Institute (NCI)
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP